|
Table 3: The use of Calcium antagonists in dermatology |
|
|||||||||||||
|
|
NIF |
NIF SR |
VER |
DIL |
DIL SR |
AML |
ISR |
NIC/ NIC SR |
FEL |
NIM |
NITR |
NIS
|
LAC |
|
|
Systemic administration |
||||||||||||||
|
Raynaud’s phenomenon |
|
1st 10-20 mg QDS up to 180mg |
|
60-120mg BD/TDS |
120-300mg OD |
2.5-5mg OD |
2.5-5mg BD |
20-30mg TD/30-60mg BD |
10mg OD |
|
|
10-40mg OD |
|
|
|
Chilblains |
|
1st 10-20mg TDS |
|
|
|
|
|
|
|
|
|
|
|
|
|
Calcinosis cutis++ |
|
|
|
240-480mg/ day |
|
|
|
|
|
|
|
|
|
|
|
Chronic Anal Fissures++ |
20mg BD |
|
|
60mg BD |
|
|
|
|
|
|
|
|
6mg OD |
|
|
Skin Flaps* |
+ |
|
+ |
+ |
|
|
|
|
|
+ |
+ |
|
|
|
|
Topical administration |
||||||||||||||
|
Keloids++ |
|
|
2.5mg/ml-0.5-2ml |
|
|
|
|
|
|
|
|
|
|
|
|
Burn scars++ |
||||||||||||||
|
Chronic Anal Fissures++ |
0.3% BD |
|
|
2%- BD |
|
|
|
|
|
|
|
|
|
|
|
Skin Flaps* |
+ |
|
+ |
+ |
|
|
|
|
|
|
+ |
|
|
|
|
NIF=Nifedipine, NIF SR=Nifedipine sustained release, VER=Verapamil, DIL=Diltiazem, DIL SR= diltiazem sust. release, AML=Amlodipine, ISR=Isradipine, NIC=Nicardipine, NIC SR=Nicardipine sust. release, FEL=Felodipine, NIM=Nimodipine, NITR=Nitrendipine, NIS
|
||||||||||||||
|
1st : First line option ++: Research based indications *: In experimental models |
||||||||||||||